Analyzing Structure Therapeutics (NASDAQ:GPCR) and HUTCHMED (NASDAQ:HCM)

Structure Therapeutics (NASDAQ:GPCR) and HUTCHMED (NASDAQ:HCM) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings and dividends.

Profitability

This table compares Structure Therapeutics and HUTCHMED’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-25.56%	-24.31%
HUTCHMED	N/A	N/A	N/A

Risk & Volatility

Structure Therapeutics has a beta of -1.43, meaning that its stock price is 243% less volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.23, meaning that its stock price is 77% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Structure Therapeutics and HUTCHMED, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2	1	12	3	2.89
HUTCHMED	2	2	1	1	2.17

Structure Therapeutics currently has a consensus price target of $110.91, indicating a potential upside of 105.16%. HUTCHMED has a consensus price target of $14.87, indicating a potential upside of 19.60%. Given Structure Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Structure Therapeutics is more favorable than HUTCHMED.

Valuation & Earnings

This table compares Structure Therapeutics and HUTCHMED”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20 million	($1.00)	-54.06
HUTCHMED	$548.51 million	3.95	$456.91 million	N/A	N/A

HUTCHMED has higher revenue and earnings than Structure Therapeutics.

Institutional & Insider Ownership

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 8.8% of HUTCHMED shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by insiders. Comparatively, 3.6% of HUTCHMED shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Structure Therapeutics beats HUTCHMED on 6 of the 11 factors compared between the two stocks.

About Structure Therapeutics

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

About HUTCHMED

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.